Public internet data has been largely exhausted for training AI models. The real competitive advantage and source for next-generation, specialized AI will be the vast, untapped reservoirs of proprietary data locked inside corporations, like R&D data from pharmaceutical or semiconductor companies.

The next leap in biotech moves beyond applying AI to existing data. CZI pioneers a model where 'frontier biology' and 'frontier AI' are developed in tandem. Experiments are now designed specifically to generate novel data that will ground and improve future AI models, creating a virtuous feedback loop.

To break the data bottleneck in AI protein engineering, companies now generate massive synthetic datasets. By creating novel "synthetic epitopes" and measuring their binding, they can produce thousands of validated positive and negative training examples in a single experiment, massively accelerating model development.

AI models trained on descriptive data (e.g., RNA-seq) can classify cell states but fail to predict how to transition a diseased cell to a healthy one. True progress requires generating massive "causal" datasets that show the effects of specific genetic perturbations.

The future of valuable AI lies not in models trained on the abundant public internet, but in those built on scarce, proprietary data. For fields like robotics and biology, this data doesn't exist to be scraped; it must be actively created, making the data generation process itself the key competitive moat.

The vague concept of a 'data network effect' is now a real defensibility strategy in AI. The key is having a *live*, constantly updating proprietary dataset (e.g., real-time health data). This allows a commodity model to deliver superior results compared to a state-of-the-art model without access to that live data.

A new 'Tech Bio' model inverts traditional biotech by first building a novel, highly structured database designed for AI analysis. Only after this computational foundation is built do they use it to identify therapeutic targets, creating a data-first moat before any lab work begins.

Achieving explainability in AI for drug development isn't about post-hoc analysis. It requires building models from the ground up using inherently interpretable data like RNA sequencing and mutational profiles. When the inputs are explainable, the model's outputs become explainable by design.

While petabytes of observational DNA sequence data exist, it's insufficient for the next wave of AI. The key to creating powerful, functional models is generating causal data—from experiments that systematically test function—which is a current data bottleneck.